Horizon Therapeutics (HPTX) and Fortress Biotech (FBIO) Head to Head Analysis

Horizon Therapeutics (NASDAQ: HPTX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap biopharmaceuticals companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Horizon Therapeutics and Fortress Biotech’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Horizon Therapeutics N/A N/A N/A ($0.03) -1,533.00
Fortress Biotech $16.48 million 10.02 -$55.09 million ($1.83) -1.78

Horizon Therapeutics has higher earnings, but lower revenue than Fortress Biotech. Horizon Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Horizon Therapeutics and Fortress Biotech, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Horizon Therapeutics 0 0 0 0 N/A
Fortress Biotech 0 0 4 0 3.00

Fortress Biotech has a consensus target price of $11.00, indicating a potential upside of 237.42%. Given Fortress Biotech’s higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Horizon Therapeutics.

Profitability

This table compares Horizon Therapeutics and Fortress Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Horizon Therapeutics 23.13% 21.30% 15.42%
Fortress Biotech -65.80% -61.43% -33.68%

Insider & Institutional Ownership

12.1% of Fortress Biotech shares are owned by institutional investors. 33.3% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Fortress Biotech beats Horizon Therapeutics on 6 of the 10 factors compared between the two stocks.

Horizon Therapeutics Company Profile

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Fortress Biotech Company Profile

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply